The Evolving Drug Safety Landscape: Implications for Pharma - Pharmaceutical Executive


The Evolving Drug Safety Landscape: Implications for Pharma

A webinar outlining the implications of the changing regulatory landscape on the industry in the short to medium term — and what could be considered in developing strategies to increase the safety profile of products — is being hosted by ICON on Wednesday 9 December at 4 pm GMT. 'Politics, Regulators and Clinical Research' will feature panelists including ICON's Suzanne Gagnon, IMS Health's Nigel Burrows and Christopher-Paul Milne, associate director of the Tufts Center for the Study of Drug Development.

Senior pharma executives involved in the drug safety or/and outsourcing strategies for their organization are invited to attend the webinar, which will discuss "what the political reforms of today mean for clinical research tomorrow"; "how recently published draft regulations from the FDA (and the expected EMEA guidelines) address drug safety and what they mean for your organization"; and "what innovative strategies pharma/biotech companies can do to continue to deliver treatments in a cost effective way."

Click here to register for this event.


blog comments powered by Disqus

Serialization Summit
San Diego, CA
Feb. 27-28, 2014

Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014

ClinTech 2014
Cambridge, MA
Mar. 11-13 2014

Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Click here